急性冠状动脉综合征患者使用替格瑞洛治疗的临床效果  

Clinical Effect of Tigrilol in Patients with Acute Coronary Syndrome

作　　者：黄华 HUANG Hua(Shenyang Emergency Center,Shenyang 110006,China)

机构地区：[1]沈阳急救中心,辽宁沈阳110006

出　　处：《中国医药指南》2021年第4期49-50,共2页Guide of China Medicine

摘　　要：目的研讨使用替格瑞洛治疗急性冠状动脉综合征(ACS)的临床疗效及对患者血小板计数、血清炎性因子水平的影响。方法择取2017年2月至2019年3月本院接收的86例ACS患者为对象,依据治疗方法的不同将其分为试验组和参照组,各组43例,两组均施予β受体阻滞剂、硝酸酯类药物、调脂类药物、阿司匹林及低分子肝素等常规治疗,此前提下,试验组对患者予以替格瑞洛进行治疗,参照组对患者予以氯吡格雷进行治疗,测定两组患者治疗前后的血小板计数、血清炎性因子(hs-CRP、LP-PLA2)水平,并判定两组疗效。结果两组患者治疗后的血小板计数水平较治疗前显著改善(P<0.05),但两组间治疗前后血小板计数差异对比无显著性(P>0.05)。试验组临床总有效率(95.35%)显著高于参照组(76.74%),差异显著(P<0.05)。结论将替格瑞洛用于ACS患者治疗的疗效较显著,能及时抑制血小板凝聚,降低血清炎性因子水平,使各项症状得到有效改善。Objective To investigate the clinical efficacy of tigrelol in the treatment of acute coronary syndrome(ACS)and its effect on platelet count and serum inflammatory cytokines in patients.Methods We selected 86 ACS patients admitted to our hospital from February 2017 to March 2019 as subjects,according to the different method of treatment to the patients in experimental group and control group,each group 43 cases,two groups are giving beta-blockers,nitrates,regulation of lipid drug,aspirin and low molecular heparin routine therapy,this premise,the experimental group for greg los treatment to patients,control group of patients to be treated with clopidogrel,the determination of two groups of patients before and after treatment of platelet count,serum inflammatory cytokines(hs CRP,LP-PLA2)levels,and determine the curative effect of the two groups.Results The platelet count level of the two groups after treatment was significantly improved compared with that before treatment(P<0.05),but there was no significant difference between the two groups before and after treatment in platelet count(P>0.05).Through treatment,the total clinical effective rate of the experimental group(95.35%)was significantly higher than that of the control group(76.74%),and the difference between the two groups was statistically significant(P<0.05).Conclusion The treatment of patients with ACS with ticagrelor has a significant effect,which can timely inhibit platelet aggregation,reduce the level of serum inflammatory factors,and effectively improve the symptoms.

关 键 词：急性冠状动脉综合征 替格瑞洛 抗血小板凝聚 炎性因子 

分 类 号：R542.22[医药卫生—心血管疾病]